

## Anti-leishmanial and structure-activity relationship of ring substituted 3-phenyl-1-(1,4-di-N-oxide quinoxalin-2-yl)-2-propen-1-one derivatives

Asunción Burguete, Yannick Estevez<sup>1/2</sup>, Denis Castillo<sup>2</sup>, Germán González<sup>2</sup>, Raquel Villar, Beatriz Solano, Esther Vicente, Silvia Pérez Silanes, Ignacio Aldana, Antonio Monge, Michel Sauvain<sup>1</sup>, Eric Deharo<sup>1/+</sup>

Unidad de Investigación y Desarrollo de Medicamentos, Centro de Investigación en Farmacobiología Aplicada, University of Navarra, Campus Universitario, Pamplona, Spain <sup>1</sup>UMR 152, Pharmacochimie des Substances Naturelles et Pharmacophores Redox, IRD - Université Toulouse III <sup>2</sup>Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia (UPCH), Av. Honorio Delgado 430, SMP, Lima, Perú

*A series of ring substituted 3-phenyl-1-(1,4-di-N-oxide quinoxalin-2-yl)-2-propen-1-one derivatives were synthesized and tested for in vitro leishmanicidal activity against amastigotes of Leishmania amazonensis in axenic cultures and murine infected macrophages. Structure-activity relationships demonstrated the importance of a radical methoxy at position R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub>. (2E)-3-(3,4,5-trimethoxy-phenyl)-1-(3,6,7-trimethyl-1,4-dioxy-quinoxalin-2-yl)-propenone was the most active. Cytotoxicity on macrophages revealed that this product was almost six times more active than toxic.*

Key words: quinoxaline - anti-leishmanial - structure-activity - Leishmaniasis

Leishmaniasis is a tropical parasitosis caused by Trypanosomatidae of the *Leishmania* genus extended over Africa, Asia, Europe, North and South America, with an estimated 12 million people infected worldwide. Clinically, leishmaniasis occurs in visceral, cutaneous and mucocutaneous forms. Chemotherapy is restricted to pentavalent antimonials, amphotericin B and pentamidine, which require parenteral administration, are toxic, expensive and have restricted therapeutic spectrums in different clinical forms of leishmaniasis (Davis et al. 2004). Recently, miltefosine has been shown to be active by oral treatment against Bolivian mucosal leishmaniasis (Soto et al. 2007); however, this treatment is not very effective against other types of leishmaniasis (Yardley et al. 2005). In this context, the discovery of new active and promising compounds with anti-leishmanial potential remains essential for the control and prevention of leishmaniasis. Quinoxaline derivatives have been reported to have anti-protozoal activity against malaria parasites (Rangisetty et al. 2001, Zarranz et al. 2005, Marin et al. 2007) and also against promastigote forms of *Leishmania amazonensis* and *Leishmania infantum* (Guillon et al. 2007). In our efforts to identify new anti-leishmanial

drug candidates, we describe herein the relationship between structure and anti-leishmanial activity of new quinoxaline 1,4-di-N-oxide derivatives on amastigotes of *L. amazonensis* (strain MHOM/BR/76/LTB-012).

### MATERIALS AND METHODS

*Chemicals and instruments* - Alugram® SIL G/UV254 (Layer: 0.2 mm) (Macherey-Nagel GmbH & Co, KG, Postfach 101352, D-52313 Düren, Germany) was used for Thin Layer Chromatography and Silica gel 60 (0.040-0.063 mm) for Column flash Chromatography (Merck). All reagents and solvents were purchased from: Merck (Darmstadt, Germany), Scharlau (FEROSA, Barcelona, Spain), Panreac Química SA (Montcada i Reixac, Barcelona, Spain), Sigma-Aldrich Química SA, (Alcobendas, Madrid), Acros Organics (Janssen Pharmaceuticaaan 3a, 2440 Geel, België) and Lancaster (Bischheim-Strasbourg, France).

Compounds 2a-e, 3a-f, 4b and 4d (Table) were synthesized according to Burguete et al. (2007). Melting points were determined with a Mettler FP82+FP80 apparatus (Greifense, Switzerland) and have not been corrected. The <sup>1</sup>H NMR spectra were recorded on a Bruker 400 Ultrashield™ (Bruker BioSpin GmbH, Rheinstetten, Germany), using TMS as the internal standard and with CDCl<sub>3</sub> and DMSO-*d*<sub>6</sub> as the solvents.

*Distribution coefficient (LogP)* - LogP was calculated with the online software Pharma-algorithms (available from: <http://pharma-algorithms.com/>). LogP is a measure of a drug's lipophilicity and an indication of its ability to cross cell membranes (Scherrer & Howard 1977). Drugs having values of p beyond 1 are classified as lipophilic, whereas those with partition coefficients smaller than 1 are indicative of hydrophilic drugs. This can be calculated *in silico* or by using an HPLC method (Valkó 2004); the higher the value, the more lipophilic the drug.


Yannick Estevez and Denis Castillo contributed equally to this work. Financial support: A Burguete was awarded a PhD fellowship supported by the "Gobierno de Navarra"; D Castillo was supported by the Belgian Technical Cooperation of Lima, Peru.

+ Corresponding autor: [ericdeharo@gmail.com](mailto:ericdeharo@gmail.com)

Received 10 June 2008

Accepted 31 October 2008

TABLE  
Antileishmanial activity on axenic amastigotes and infection rates of *L. amazonensis* and LogP calculated *in silico* (<http://pharma-algorithms.com/>) of the tested compounds



Drugs	R6	R7	R <sub>3</sub> '	R <sub>4</sub> '	R <sub>5</sub> '	IC <sub>50</sub>	SI	IC <sub>50</sub> (IR)	LogP
2a	H	H	OCH <sub>3</sub>	OCH <sub>3</sub>	OCH <sub>3</sub>	4,9 ± 2.1	2,8	13,1	0.85
2b	H	OCH <sub>3</sub>	OCH <sub>3</sub>	OCH <sub>3</sub>	OCH <sub>3</sub>	65,6 ± 22.9	1,2	23,5	0.8
2c	H	Cl	OCH <sub>3</sub>	OCH <sub>3</sub>	OCH <sub>3</sub>	37,0 ± 7.8	4,3	23,2	1.23
2d	H	F	OCH <sub>3</sub>	OCH <sub>3</sub>	OCH <sub>3</sub>	2,7 ± 0.6	5,1	24,1	0.73
2e	CH <sub>3</sub>	CH <sub>3</sub>	OCH <sub>3</sub>	OCH <sub>3</sub>	OCH <sub>3</sub>	4,1 ± 0.5	>5,7	17,7	1.67
3a	H	H	O-CH <sub>2</sub> -O	H	H	>100	NT	-	1.49
3b	H	OCH <sub>3</sub>	O-CH <sub>2</sub> -O	H	H	>100	NT	-	1.44
3c	H	Cl	O-CH <sub>2</sub> -O	H	H	>100	NT	-	1.87
3d	H	F	O-CH <sub>2</sub> -O	H	H	>100	NT	-	1.37
3e	CH <sub>3</sub>	CH <sub>3</sub>	O-CH <sub>2</sub> -O	H	H	>100	NT	-	2.31
3f	H	CH <sub>3</sub>	O-CH <sub>2</sub> -O	H	H	>100	NT	-	1.9
4b	H	OCH <sub>3</sub>	OCH <sub>3</sub>	OH	H	5,3 ± 2.3	25,2	43,7	0.59
4d	H	F	OCH <sub>3</sub>	OH	H	6,7 ± 1.3	20,7	42,9	0.53
Amph.B						0.06 ± 0.01	73	0.6	-

IC<sub>50</sub>: concentration inhibiting 50% of the parasite growth, in μM; IR: infection rate; NT: not tested; SI: Selectivity Index (TD<sub>50</sub>/IC<sub>50</sub>).

*Activity of quinoxaline derivatives on axenic amastigotes* - Axenically grown amastigotes of *L. amazonensis* (strain MHOM/BR/76/LTB-012) were maintained by weekly sub-passages in medium for axenically grown amastigotes (extensively described by Sereno & Lemesre 1997a) and supplemented with 20% of foetal bovine serum at 32°C with 5% CO<sub>2</sub> in 25 cm<sup>2</sup> tissue culture flasks. Cultures were initiated with 10<sup>6</sup> amastigotes/mL in 25 cm<sup>2</sup> tissue culture flasks with 5 mL of media. In order to determine the activity of the drugs, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) micromethod was used as previously described by Sereno and Lemesre (1997b). Briefly, 100 μL of axenically grown amastigotes, from late LogPhase of growth, were seeded in 96-well flat bottom microtiter plates. The drugs, dissolved in dimethylsulfoxide (DMSO), were added at final concentrations ranging from 100 to 1 μg/mL. All experiments were performed in triplicate. The final DMSO concentration was never greater than 0.1%. After 72 h of incubation, 10 μL of MTT (10 mg/mL) was added to each well and plates were further incubated for 4 h. The enzymatic reaction was then stopped with 100 μL of 50% isopropanol (v/v) -10% sodium dodecyl sulphate (w/v) and incubated for an additional 30 min, under agitation, at rt. Finally, the optical density was read at 590 nm with a 96-well scanner (Bio-Rad).

The percentage of growth inhibition of the parasite was calculated by the following formula:

$$\frac{(\text{OD control} - \text{OD drugs}) \times 100}{\text{OD control}} = \% \text{ of inhibition}$$

The dose inhibiting 50% of the parasite growth (IC<sub>50</sub>) was calculated (Excel software).

Reference compounds were amphotericin B and gluconate antimoniate of meglumine (Glucantime).

*Activity on infected macrophages* - Macrophages were harvested from peritoneal cavities of 6-8 week-old female BALB/c mice in ice-cold M199 medium (supplemented with 10% foetal bovine serum), adapted from Sauvain et al. (1993). The cells were plated at 10<sup>6</sup>/mL on glass coverslips and incubated at 37°C under an atmosphere of 5% CO<sub>2</sub> for 24 h. Non-adherent cells were removed by washing with pre-warmed M199 medium. Medium was then replaced by a suspension of amastigotes, using an infection ratio of 3/1 amastigotes/macrophages, for 2 h at 32°C in 5% CO<sub>2</sub>. Cells were then washed three times with pre-warmed M199 medium to remove free parasites. The drug to be tested, dissolved in DMSO, was then added and incubated for 48 h at 37°C in 5% CO<sub>2</sub>. Cultures were subsequently fixed with absolute methanol, stained with Giemsa and examined by light microscopy. The number of intracellular amastigotes was determined by counting amastigotes in 300 macrophages. All experiments were performed in triplicate.

The infection rates (IR) were calculated according to Delorenzi et al. (2001) and Monzote et al. (2004). Then, the drug concentration able to reduce the IR in macrophages by 50%, IC<sub>50</sub> (IR), was calculated using the PROBIT formula in Excel.

*Cytotoxicity on macrophages* - Murine macrophages were treated with the drug and their viabilities were determined by trypan blue dye exclusion. Living cells exclude the dye, whereas dead cells take up the blue dye. Resident mouse macrophages adhering to 96-well plates

were incubated for 24 h at 37°C in 5% CO<sub>2</sub>. Drugs were then added and cells returned to culture for 48 h. Finally, macrophages were incubated with 0.4% trypan blue solution and the viable cells were enumerated with a microscope. One hundred cells were counted for each concentration and the number of viable cells that excluded trypan blue was determined to calculate percentage of viability. The drug dose killing 50% of the macrophages (TD<sub>50</sub>) was then determined with the PROBIT formula of Excel software. Amphotericin B was used as a control.

## RESULTS AND DISCUSSION

Anti-leishmanial activities of the studied compounds are listed in Table. Compounds 3a-f were inactive against axenic amastigotes with an IC<sub>50</sub> > 100 µM. Compounds in series 2 and 4 presented the best anti-leishmanial activities, displaying IC<sub>50</sub> ranging from 2.8 to 65.6 µM. We can therefore say that when the hydroxy and methoxy groups are substituted by a methylenedioxy group, the activity decreases dramatically. Moreover, product 2d with a fluorine atom in R7 was the most active against axenic amastigotes with an IC<sub>50</sub> at around 3 µM. The active compounds (series: 2 and 4) were then evaluated on non-infected macrophages to determinate their selectivity index. Products 4b and 4d were the most selective, followed by 2e, 2d and 2c; products 2a and 2b were the least selective. Amphotericin B was also tested against non-infected macrophages and was shown to be around 70 times less cytotoxic on macrophages than on axenic amastigotes.

In order to gain further insight into the ability of these drugs to cross cell membranes, LogP values were calculated by computational analysis with using the help of Pharma-algorithms (available from <http://pharma-algorithms.com>) *in silico*. Compound 2e was shown to be the most lipophilic among the most active compounds. Interestingly, apart from 2e, the active compounds against axenic amastigotes had LogP values < 1.25, while inactive drugs showed LogP values > 1.25. These results are in agreement with previously published results by Valderama et al. (2005) showing that the lipophilicity of leishmanicidal quinones is correlated with their leishmanicidal activity. Compounds 4b and 4d, with a hydroxyl group in the structure, were less active (IC<sub>50</sub> (IR) > 40 µM) against *L. amazonensis* infected macrophages than compounds in group 2, with three methoxy groups. Interestingly, 2b, 2c and 2d have similar IC<sub>50</sub> (IR) (> 20 µM), while 2a and 2e have the lowest IC<sub>50</sub> (IR) (around 13.1 µM and 17.7 µM respectively); with compound 2e showing less cytotoxicity than 2a.

Thus, our results suggest that compound 2e, (2E)-3-(3,4,5-trimethoxy-phenyl)-1-(3,6,7-trimethyl-1,4-dioxoquinoxalin-2-yl)-propenone, should be considered for further *in vivo* studies against *Leishmania* parasites.

## ACKNOWLEDGMENTS

To Colleen McClean and Claudia Landini, for the critical reading of the manuscript.

## REFERENCES

- Burguete A, Pontiki E, Hadjipavlou-Litina D, Villar R, Vicente E, Solano B, Ancizu S, Pérez-Silanes S, Aldana I, Monge A 2007. Synthesis and anti-inflammatory/antioxidant activities of some new ring substituted 3-phenyl-1-(1,4-di-N-oxide quinoxalin-2-yl)-2-propen-1-one derivatives and of their 4,5-dihydro-(1H)-pyrazole analogues. *Bioorg Med Chem Lett* 17: 6439-6443.
- Davis AJ, Murray HW, Handman E 2004. Drugs against leishmaniasis: a synergy of technology and partnerships. *Trends in Parasitol* 20: 73-76.
- Delorenzi JC, Attias M, Gattass CR, Andrade M, Rezende C, Pinto AC, Henriques AT, Bou-Habib DC, Saraiva E 2001. Antileishmanial activity of an indole alkaloid from *Peschiera australis*. *Antimicrob Agents Chemother* 45: 1349-1354.
- Guillon J, Forfar I, Mamani-Matsuda M, Desplat V, Saliege M, Thiolat D, Massip S, Tabourier A, Leger JM, Dufaure B, Haumont G, Jarry C, Mossalayi D 2007. Synthesis, analytical behaviour and biological evaluation of new 4-substituted pyrrolo[1,2-a]quinoxalines as antileishmanial agents. *Bioorg Med Chem* 15: 194-210.
- Marin A, Moreira Lima L, Solano B, Vicente E, Pérez Silanes S, Maurel S, Sauvain M, Aldana I, Monge A, Deharo E 2007. Antiplasmodial structure-activity relationship of 3-trifluoromethyl-2-arylcarbonylquinoxaline 1,4-di-N-oxide derivatives. *Exp Parasitol* 118: 25-31.
- Monzote Fidalgo L, Montalvo Alvarez AM, Geigel LF, Pérez Pineiro R, Suárez Navarro M, Rodríguez Cabrera H 2004. Effect of thiazidine derivatives on intracellular amastigotes of *Leishmania amazonensis*. *Mem Inst Oswaldo Cruz* 99: 329-330.
- Rangisetty JB, Gupta CNVHB, Prasad AL, Srinivas P, Sridhar N, Parimoo P, Veeranjanyulu A 2001. Synthesis of new arylaminoquinoxalines and their antimalarial activity in mice. *J Pharm Pharmacol* 53: 1409-1413.
- Sauvain M, Dedet JP, Kunesch N, Poisson J, Gayral P, Gantier JC, Kunesch G 1993. *In vitro* and *in vivo* leishmanicidal activities of natural and synthetic quinoids. *Phytother Res* 7: 167-171.
- Scherrer RA, Howard SM 1977. Use of distribution coefficients in quantitative structure-activity relationships. *J Med Chem* 20: 53-58.
- Sereno D, Lemesre JL 1997a. Axenically cultured amastigote forms as an *in vitro* model for investigation of antileishmanial agents. *Antimicrob Agents Chemother* 41: 972-976.
- Sereno D, Lemesre JL 1997b. Use of an enzymatic micromethod to quantify amastigotes stage of *Leishmania amazonensis* *in vitro*. *Parasitol Res* 83: 401-403.
- Soto J, Toledo J, Valda L, Balderrama M, Rea I, Parra R, Ardiles J, Soto P, Gomez A, Molleda F, Fuentelsaz C, Anders G, Sindermann H, Engel J, Berman J 2007. Treatment of Bolivian mucosal leishmaniasis with miltefosine clinical infectious diseases. *Clin Infect Dis* 44: 350-356.
- Valderrama JA, Zamorano C, González MF, Prina E, Fournet A 2005. Studies on quinones. Part 39: Synthesis and leishmanicidal activity of acylchloroquinones and hydroquinones. *Bioorg Med Chem* 1: 4153-4159.
- Valkó K 2004. Application of high-performance liquid chromatography based measurements of lipophilicity to model biological distribution. *J Chromatogr* 1037: 299-310.
- Yardley V, Croft SL, de Doncker S, Dujardin JC, Koirala S, Rijal S, Miranda C, Llanos-Cuentas A, Chappuis F 2005. The sensitivity of clinical isolates of *Leishmania* from Peru and Nepal to miltefosine. *Am J Trop Med Hyg* 73: 272-275.
- Zarranz B, Jaso A, Aldana I, Monge A, Maurel S, Deharo E, Jullian V, Sauvain M 2005. Synthesis and antimalarial activity of new 3-arylquinoxaline-2-carbonitrile derivatives. *Arzneimittelforschung* 55: 754-761.